US 12,274,701 B2
Compositions and methods for treating retinal degradation
Jayakrishna Ambati, Lexington, KY (US); and Benjamin Fowler, Lexington, KY (US)
Assigned to University of Kentucky Research Foundation, Lexington, KY (US)
Filed by University of Kentucky Research Foundation, Lexington, KY (US)
Filed on Mar. 13, 2023, as Appl. No. 18/183,110.
Application 18/183,110 is a continuation of application No. 17/116,755, filed on Dec. 9, 2020, granted, now 11,602,535, issued on Mar. 14, 2023.
Application 17/116,755 is a continuation of application No. 16/361,810, filed on Mar. 22, 2019, granted, now 10,864,212, issued on Dec. 15, 2020.
Application 16/361,810 is a continuation of application No. 15/142,087, filed on Apr. 29, 2016, granted, now 10,300,057, issued on Dec. 15, 2020.
Application 15/142,087 is a continuation of application No. 14/450,000, filed on Aug. 1, 2014, granted, now 9,326,983, issued on May 3, 2016.
Claims priority of provisional application 61/987,612, filed on May 2, 2014.
Claims priority of provisional application 61/861,290, filed on Aug. 1, 2013.
Prior Publication US 2023/0218620 A1, Jul. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/506 (2006.01); A61K 31/513 (2006.01); A61K 31/52 (2006.01); A61K 31/7052 (2006.01); A61K 31/706 (2006.01); A61K 31/7064 (2006.01); A61K 31/7068 (2006.01); A61K 31/7072 (2006.01); A61K 31/7076 (2006.01); C07D 405/04 (2006.01); C07D 411/04 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/506 (2013.01) [A61K 31/513 (2013.01); A61K 31/52 (2013.01); A61K 31/7052 (2013.01); A61K 31/706 (2013.01); A61K 31/7064 (2013.01); A61K 31/7068 (2013.01); A61K 31/7072 (2013.01); A61K 31/7076 (2013.01); C07D 405/04 (2013.01); C07D 411/04 (2013.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01)] 17 Claims
 
1. A method of blocking inflammasome activation, the method comprising administering to a patient in need thereof a nucleoside reverse transcriptase inhibitor (NRTI), whereby the NRTI blocks inflammasome activation, wherein the NRTI is selected from stavudine (d4T), lamivudine (3TC), abacavir (ABC), 5′-methoxy-d4T, or combinations thereof.